Effect of statin therapy on vaspin levels in type 2 diabetic patients

Sayer I Al-Azzam,1 Karem H Alzoubi,1 Jaafar Abu Abeeleh,2 Nizar M Mhaidat,1 Mahmoud Abu-Abeeleh31Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 2Department of Pharmacy, Royal Medical Services, Amman, 3Department of Surgery, Division of Cardi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Al-Azzam SI, Alzoubi KH, Abu Abeeleh J, Mhaidat NM, Abu-Abeeleh M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/eb835243a019475a80fd6e5a9c9de0e3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb835243a019475a80fd6e5a9c9de0e3
record_format	dspace
spelling	oai:doaj.org-article:eb835243a019475a80fd6e5a9c9de0e32021-12-02T05:50:28ZEffect of statin therapy on vaspin levels in type 2 diabetic patients1179-1438https://doaj.org/article/eb835243a019475a80fd6e5a9c9de0e32013-02-01T00:00:00Zhttp://www.dovepress.com/effect-of-statin-therapy-on-vaspin-levels-in-type-2-diabetic-patients-a12261https://doaj.org/toc/1179-1438Sayer I Al-Azzam,1 Karem H Alzoubi,1 Jaafar Abu Abeeleh,2 Nizar M Mhaidat,1 Mahmoud Abu-Abeeleh31Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 2Department of Pharmacy, Royal Medical Services, Amman, 3Department of Surgery, Division of Cardiothoracic Surgery, Faculty of Medicine, The University of Jordan, Amman, JordanBackground: Statins are commonly used antihyperlipidemic agents, with anti-inflammatory and immunomodulatory properties that are thought to account for a significant portion of their ability to protect against atherosclerosis and cardiovascular disease. Vaspin, a visceral adipose tissue-derived serine protease inhibitor, is an emerging adipokine with important insulin-sensitizing, cardioprotective, and antiatherosclerotic properties in patients with diabetes. In this randomized controlled clinical trial, we evaluated the effect of statin therapy on vaspin levels in patients with type 2 diabetes mellitus.Methods: Patients were divided into two groups, ie, those receiving simvastatin (study group, n = 33), and those who did not (control group, n = 29). Patient data, blood biochemistry, and vaspin levels were recorded at the beginning of the study (baseline) and after 8 weeks (end of the study).Results: After 8 weeks of treatment, vaspin levels were increased in patients treated with simvastatin (504.58 &plusmn; 203.07 pg/mL at baseline versus 629.15 &plusmn; 68.39 pg/mL after 8 weeks, P &lt; 0.01), but not in patients who were not treated with simvastatin (613.33 &plusmn; 357.53 pg/mL at baseline versus 582.37 &plusmn; 84.63 pg/mL after 8 weeks, P &gt; 0.05). In addition, the lipid-lowering effect of simvastatin was reflected in a statistically significant reduction in total cholesterol in the study group (220.75 &plusmn; 55.66 mg/dL at baseline versus 201.90 &plusmn; 53.65 mg/dL after 8 weeks P &lt; 0.01) but not in the control group (214.24 &plusmn; 47.2 mg/dL at baseline versus 215.72 &plusmn; 43.65 mg/dL after 8 weeks, P &gt; 0.05) and in a statistically significant reduction in triglyceride levels in the study group (265.8 &plusmn; 210.41 mg/dL at baseline versus 223.03 &plusmn; 178.67 mg/dL after 8 weeks, P &lt; 0.05) but not in the control group (225.44 &plusmn; 115.13 mg/dL at baseline versus 215.58 &plusmn; 110.2 mg/dL after 8 weeks, P &gt; 0.05). Mean vaspin levels were significantly higher in the study group than in the control group.Conclusion: These results indicate that statin therapy increases plasma vaspin levels in addition to having a lipid-lowering effect. This could be a mechanism underlying the pleiotropic effects seen with statins, including their cardioprotective and antiatherosclerotic effects.Keywords: vaspin, statins, diabetes, adipokinesAl-Azzam SIAlzoubi KHAbu Abeeleh JMhaidat NMAbu-Abeeleh MDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss Issue 1, Pp 33-38 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Al-Azzam SI Alzoubi KH Abu Abeeleh J Mhaidat NM Abu-Abeeleh M Effect of statin therapy on vaspin levels in type 2 diabetic patients
description	Sayer I Al-Azzam,1 Karem H Alzoubi,1 Jaafar Abu Abeeleh,2 Nizar M Mhaidat,1 Mahmoud Abu-Abeeleh31Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 2Department of Pharmacy, Royal Medical Services, Amman, 3Department of Surgery, Division of Cardiothoracic Surgery, Faculty of Medicine, The University of Jordan, Amman, JordanBackground: Statins are commonly used antihyperlipidemic agents, with anti-inflammatory and immunomodulatory properties that are thought to account for a significant portion of their ability to protect against atherosclerosis and cardiovascular disease. Vaspin, a visceral adipose tissue-derived serine protease inhibitor, is an emerging adipokine with important insulin-sensitizing, cardioprotective, and antiatherosclerotic properties in patients with diabetes. In this randomized controlled clinical trial, we evaluated the effect of statin therapy on vaspin levels in patients with type 2 diabetes mellitus.Methods: Patients were divided into two groups, ie, those receiving simvastatin (study group, n = 33), and those who did not (control group, n = 29). Patient data, blood biochemistry, and vaspin levels were recorded at the beginning of the study (baseline) and after 8 weeks (end of the study).Results: After 8 weeks of treatment, vaspin levels were increased in patients treated with simvastatin (504.58 &plusmn; 203.07 pg/mL at baseline versus 629.15 &plusmn; 68.39 pg/mL after 8 weeks, P &lt; 0.01), but not in patients who were not treated with simvastatin (613.33 &plusmn; 357.53 pg/mL at baseline versus 582.37 &plusmn; 84.63 pg/mL after 8 weeks, P &gt; 0.05). In addition, the lipid-lowering effect of simvastatin was reflected in a statistically significant reduction in total cholesterol in the study group (220.75 &plusmn; 55.66 mg/dL at baseline versus 201.90 &plusmn; 53.65 mg/dL after 8 weeks P &lt; 0.01) but not in the control group (214.24 &plusmn; 47.2 mg/dL at baseline versus 215.72 &plusmn; 43.65 mg/dL after 8 weeks, P &gt; 0.05) and in a statistically significant reduction in triglyceride levels in the study group (265.8 &plusmn; 210.41 mg/dL at baseline versus 223.03 &plusmn; 178.67 mg/dL after 8 weeks, P &lt; 0.05) but not in the control group (225.44 &plusmn; 115.13 mg/dL at baseline versus 215.58 &plusmn; 110.2 mg/dL after 8 weeks, P &gt; 0.05). Mean vaspin levels were significantly higher in the study group than in the control group.Conclusion: These results indicate that statin therapy increases plasma vaspin levels in addition to having a lipid-lowering effect. This could be a mechanism underlying the pleiotropic effects seen with statins, including their cardioprotective and antiatherosclerotic effects.Keywords: vaspin, statins, diabetes, adipokines
format	article
author	Al-Azzam SI Alzoubi KH Abu Abeeleh J Mhaidat NM Abu-Abeeleh M
author_facet	Al-Azzam SI Alzoubi KH Abu Abeeleh J Mhaidat NM Abu-Abeeleh M
author_sort	Al-Azzam SI
title	Effect of statin therapy on vaspin levels in type 2 diabetic patients
title_short	Effect of statin therapy on vaspin levels in type 2 diabetic patients
title_full	Effect of statin therapy on vaspin levels in type 2 diabetic patients
title_fullStr	Effect of statin therapy on vaspin levels in type 2 diabetic patients
title_full_unstemmed	Effect of statin therapy on vaspin levels in type 2 diabetic patients
title_sort	effect of statin therapy on vaspin levels in type 2 diabetic patients
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/eb835243a019475a80fd6e5a9c9de0e3
work_keys_str_mv	AT alazzamsi effectofstatintherapyonvaspinlevelsintype2diabeticpatients AT alzoubikh effectofstatintherapyonvaspinlevelsintype2diabeticpatients AT abuabeelehj effectofstatintherapyonvaspinlevelsintype2diabeticpatients AT mhaidatnm effectofstatintherapyonvaspinlevelsintype2diabeticpatients AT abuabeelehm effectofstatintherapyonvaspinlevelsintype2diabeticpatients
_version_	1718400266924982272

Effect of statin therapy on vaspin levels in type 2 diabetic patients

Ejemplares similares